Articles

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

National and Kapodistrian University of Athens, Athens, Greece
Odette Cancer Centre, Toronto, ON, Canada
CHU Purpan/IUCT Oncopole, Toulouse, France
West China Hospital of Sichuan University, Chengdu, China
Arcispedale S. Maria Nuova, Reggio Emilia, Italy
Hôpital Robert Debré, Paris, France
Staedtische Kliniken Frankfurt am Main Höchst, Frankfurt, Germany
National Cancer Center, Goyang-si Gyeonggi-do, South Korea
Hôpital Henri Mondor, Creteil, France
Centre Henri Becquerel, Rouen, France
Ottawa Hospital, ON, Canada
Hematology, Hôpital de Versailles, Le Chesnay, France
CHU Angers, Angers, France
Royal Bournemouth Hospital, Dorset, England, UK
Hospital Center, Vannes, France
CHU Limoges, France
Hôpital du Sacré-Coeur de Montréal, QB, Canada
Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Fred Hutchinson Cancer Center, Seattle, WA, USA
University Hospital VUB-Myeloma Center Brussels, Vrije Universiteit Brussels, Brussels, Belgium
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Service des Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, France
Vol. 101 No. 3 (2016): March, 2016 https://doi.org/10.3324/haematol.2015.133629